A Delaware district court must maintain its pause of an order that the FDA delay final approval of MSN Laboratories Pvt. Ltd.

MSN Laboratories Pvt. Ltd. is appealing rulings that block the early launch of its copy of Entresto and preserve Novartis ...

So Entresto is ready to be rolled out in the US with a price tag of around $4,500 a year. Novartis has hinted at an outcomes-based pricing plan but there are no details of any scheme or how it ...

Have you been prescribed Entresto or Jardiance? Deep discounts on Medicare drugs coming ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...

Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs ...

Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year ...

Case Name: In re Entresto, 125 F.4th 1090 (Fed. Cir. Jan. 10, 2025) (Circuit Judges Lourie, Prost, and Reyna presiding; Opinion by Lourie, C.J.) (Appeal from D. Del ...

Entresto, Cosentyx, and Kisqali sales soared; Kisqali jumped 56% cc to $956 million with 87% U.S. growth from early breast cancer use. Get prepared for the Fed’s next move—live with Matt Maley ...

Swiss pharma giant Novartis AGNVS reported better-than-expected results for the first quarter of 2025 and upped its annual ...

The Basel-based drugmaker is bracing for headwinds from the U.S. patent expiry for its biggest moneymaker Entresto. It expects U.S. competition for Entresto, cancer drug Tasigna and Promacta ...